Discussion on FALCON: Impact of 18F-fluciclovine PET/CT on Clinical Management Choices for Men with Biochemically Recurrent Prostate Cancer
February 15, 2018
Dr. Thomas Keane provides a commentary on the The FALCON Trial, the impact of 18F-fluciclovine PET/CT on clinical management choices for men with biochemically recurrent prostate cancer presented at the recent 2018 American Society of Clinical Oncology Genitourinary (ASCO GU) Cancers Symposium.
Eugene Jueren Teoh, MBBS, MRCP from the University of Oxford presented this study beginning with the extent of local recurrence detection and of metastases in biochemical recurrence (BCR) of prostate cancer (PC) which facilitates selection of appropriate treatment. The FALCON trial assessed the impact of 18F-fluciclovine PET/CT on the clinical management of men with PC BCR following initial radical therapy.
Dr. Thomas Keane reviews the methods, primary, and secondary outcome measures, and inclusion criteria. Men being considered for curative-intent salvage therapy following BCR were recruited at 6 different UK sites. Management plans were documented prior to and following 18F-fluciclovine PET/CT imaging.
This prospective trial demonstrates that 18F-fluciclovine PET/CT has substantial impact on clinical decisions for men with PC BCR after curative-intent primary therapy.
Thomas E. Keane, MBBCh, FRCSI, FACS